Сердечно-сосудистые заболевания и злокачественные новообразования — что общего?

Сердечно-сосудистые заболевания как злокачественные новообразования занимают лидирующие позиции в структуре общей смертности. Одним из распространённых побочных эффектов лечения злокачественных новообразований является кардиотоксичность, которая в последующем осложняет патогенетическую терапию образования. Целью данного обзора явилось обобщение и уточнение имеющихся представлений о влиянии различных факторов риска сердечно-сосудистых заболеваний на возникновение рака. Представленный обзор позволяет детально изучить результаты метаанализов и крупномасштабных исследований, дополняющие представление о классических поведенческих факторах, таких как курение, употребление алкоголя, нерациональное питание, и биологических факторах риска, таких как артериальная гипертензия, ожирение, сахарный диабет, отражающие вклад этих факторов в развитие не только сердечно-сосудистых, но и злокачественных новообразований. Влияние данных факторов, проанализировано с позиции патогенетических механизмов — оксидативного стресса и хронического воспаления, кардиотоксичности проводимого лечения. Также в обзоре уделяется внимание противоречивым данным в отношении влияния какого-либо фактора на возникновение данных нозологий и обобщается анализируемый материал.

1. WHO. Global Cancer Burden Rising Amid Striking Inequities. 2024.

2. Российский статистический ежегодник. М.; 2024.

3. Wilcox NS, Amit U, Reibel JB, Berlin E, Howell K, et al. Cardiovascular disease and cancer: shared risk factors and mechanisms. Nat Rev Cardiol. 2024;21(9):617-631. https://doi.org/10.1038/s41569-024-01017-x.

4. Gao H, Chen Z, Yao Y, He Y, Hu X. Common biological processes and mutual crosstalk mechanisms between cardiovascular disease and cancer. Front Oncol. 2024;14:1453090. https://doi.org/10.3389/fonc.2024.1453090

5. Ewer MS, Yusuf SW, Asmis R, Abe JI. Editorial: Case reports in cardio-oncology: 2022. Front Cardiovasc Med. 2023;10:1235015. https://doi.org/10.3389/fcvm.2023.1235015

6. Sturgeon KM, Deng L, Bluethmann SM, Zhou S, Trifiletti DM, et al. A population-based study of cardiovascular disease mortality risk in US cancer patients. Eur Heart J. 2019;40(48):3889-3897. https://doi.org/10.1093/eurheartj/ehz766

7. Lyon AR, López-Fernández T, Couch LS, Asteggiano R, Aznar MC, et al. 2022 ESC Guidelines on cardio-oncology developed in collaboration with the European Hematology Association (EHA), the European Society for Therapeutic Radiology and Oncology (ESTRO) and the International Cardio-Oncology Society (IC-OS). Eur Heart J Cardiovasc Imaging. 2022;23(10):e333-e465. Erratum in: Eur Heart J Cardiovasc Imaging. 2023;24(6):e98. https://doi.org/10.1093/ehjci/jeac106

8. Satpathy C, Kumar Mishra T, Singh S, Jha AK. Reverse cardio-oncology: A budding concept. Indian Heart J. 2023;75(6):398-402. https://doi.org/10.1016/j.ihj.2023.09.004

9. Raisi-Estabragh Z, Cooper J, McCracken C, Crosbie EJ, Walter FM, et al. Incident cardiovascular events and imaging phenotypes in UK Biobank participants with past cancer. Heart. 2023;109(13):1007-1015. https://doi.org/10.1136/heartjnl-2022-321888

10. Jiang C, Chen YX, Geng QS, Liu AB. Prevalence and clinical risk factors of cardiovascular disease in patients with cancer: a cross-sectional study. BMC Cardiovasc Disord. 2025;25(1):526. https://doi.org/10.1186/s12872-025-04976-2

11. Allison JD, Tanavin T, Yang Y, Birnbaum G, Khalid U. Various Manifestations of 5-Fluorouracil Cardiotoxicity: A Multicenter Case Series and Review of Literature. Cardiovasc Toxicol. 2020;20(4):437-442. https://doi.org/10.1007/s12012-020-09562-w

12. Shiga T, Hiraide M. Cardiotoxicities of 5-Fluorouracil and Other Fluoropyrimidines. Curr Treat Options Oncol. 2020;21(4):27. https://doi.org/10.1007/s11864-020-0719-1

13. Herrmann J. Vascular toxic effects of cancer therapies. Nat Rev Cardiol. 2020;17(8):503-522. https://doi.org/10.1038/s41569-020-0347-2

14. Banks E, Joshy G, Korda RJ, Stavreski B, Soga K, et al. Tobacco smoking and risk of 36 cardiovascular disease subtypes: fatal and non-fatal outcomes in a large prospective Australian study. BMC Med. 2019;17(1):128. https://doi.org/10.1186/s12916-019-1351-4

15. Pirro M, Ricciuti B, Rader DJ, Catapano AL, Sahebkar A, Banach M. High density lipoprotein cholesterol and cancer: Marker or causative? Prog Lipid Res. 2018;71:54-69. https://doi.org/10.1016/j.plipres.2018.06.001

16. Cohen JB, Geara AS, Hogan JJ, Townsend RR. Hypertension in Cancer Patients and Survivors: Epidemiology, Diagnosis, and Management. JACC CardioOncol. 2019;1(2):238-251. https://doi.org/10.1016/j.jaccao.2019.11.009

17. Radišauskas R, Kuzmickienė I, Milinavičienė E, Everatt R. Hypertension, serum lipids and cancer risk: A review of epidemiological evidence. Medicina (Kaunas). 2016;52(2):89-98. https://doi.org/10.1016/j.medici.2016.03.002

18. Nam GE, Baek SJ, Choi HB, Han K, Kwak JM, et al. Association between Abdominal Obesity and Incident Colorectal Cancer: A Nationwide Cohort Study in Korea. Cancers (Basel). 2020;12(6):1368. https://doi.org/10.3390/cancers12061368

19. Kim CS, Han KD, Choi HS, Bae EH, Ma SK, Kim SW. Association of Hypertension and Blood Pressure With Kidney Cancer Risk: A Nationwide Population-Based Cohort Study. Hypertension. 2020;75(6):1439-1446. https://doi.org/10.1161/HYPERTENSIONAHA.120.14820

20. Xuan K, Zhao T, Sun C, Patel AS, Liu H, et al. The association between hypertension and colorectal cancer: a meta-analysis of observational studies. Eur J Cancer Prev. 2021;30(1):84-96. https://doi.org/10.1097/CEJ.0000000000000578

21. Volpe M, Gallo G. Obesity and cardiovascular disease: An executive document on pathophysiological and clinical links promoted by the Italian Society of Cardiovascular Prevention (SIPREC). Front Cardiovasc Med. 2023;10:1136340. https://doi.org/10.3389/fcvm.2023.1136340

22. Koliaki C, Liatis S, Kokkinos A. Obesity and cardiovascular disease: revisiting an old relationship. Metabolism. 2019;92:98-107. https://doi.org/10.1016/j.metabol.2018.10.011

23. Li B, Leung JCK, Chan LYY, Yiu WH, Tang SCW. A global perspective on the crosstalk between saturated fatty acids and Toll-like receptor 4 in the etiology of inflammation and insulin resistance. Prog Lipid Res. 2020;77:101020. https://doi.org/10.1016/j.plipres.2019.101020

24. Xu J, Lin H, Wu G, Zhu M, Li M. IL-6/STAT3 Is a Promising Therapeutic Target for Hepatocellular Carcinoma. Front Oncol. 2021;11:760971. https://doi.org/10.3389/fonc.2021.760971

25. Yuan F, Wen W, Jia G, Long J, Shu XO, Zheng W. Serum Lipid Profiles and Cholesterol-Lowering Medication Use in Relation to Subsequent Risk of Colorectal Cancer in the UK Biobank Cohort. Cancer Epidemiol Biomarkers Prev. 2023;32(4):524-530. https://doi.org/10.1158/1055-9965.EPI-22-1170

26. Nouri M, Mohsenpour MA, Katsiki N, Ghobadi S, Jafari A, et al. Effect of Serum Lipid Profile on the Risk of Breast Cancer: Systematic Review and Meta-Analysis of 1,628,871 Women. J Clin Med. 2022;11(15):4503. https://doi.org/10.3390/jcm11154503

27. Quoc Lam B, Shrivastava SK, Shrivastava A, Shankar S, Srivastava RK. The Impact of obesity and diabetes mellitus on pancreatic cancer: Molecular mechanisms and clinical perspectives. J Cell Mol Med. 2020;24(14):7706-7716. https://doi.org/10.1111/jcmm.15413

28. Raghavan S, Vassy JL, Ho YL, Song RJ, Gagnon DR, et al. Diabetes Mellitus-Related All-Cause and Cardiovascular Mortality in a National Cohort of Adults. J Am Heart Assoc. 2019;8(4):e011295. https://doi.org/10.1161/JAHA.118.011295

29. Pryor R, Cabreiro F. Repurposing metformin: an old drug with new tricks in its binding pockets. Biochem J. 2015;471(3):307-322. https://doi.org/10.1042/BJ20150497

30. Sona MF, Myung SK, Park K, Jargalsaikhan G. Type 1 diabetes mellitus and risk of cancer: a meta-analysis of observational studies. Jpn J Clin Oncol. 2018;48(5):426-433. https://doi.org/10.1093/jjco/hyy047

31. Carstensen B, Read SH, Friis S, Sund R, Keskimäki I, et al. Cancer incidence in persons with type 1 diabetes: a fivecountry study of 9,000 cancers in type 1 diabetic individuals. Diabetologia. 2016;59(5):980-988. https://doi.org/10.1007/s00125-016-3884-9

32. Harding JL, Shaw JE, Peeters A, Cartensen B, Magliano DJ. Cancer risk among people with type 1 and type 2 diabetes: disentangling true associations, detection bias, and reverse causation. Diabetes Care. 2015;38(2):264-270. Erratum in: Diabetes Care. 2015;38(4):734-735. https://doi.org/10.2337/dc14-1996

33. Tsilidis KK, Kasimis JC, Lopez DS, Ntzani EE, Ioannidis JP. Type 2 diabetes and cancer: umbrella review of meta-analyses of observational studies. BMJ. 2015;350:g7607. https://doi.org/10.1136/bmj.g7607

34. Zhu B, Qu S. The Relationship Between Diabetes Mellitus and Cancers and Its Underlying Mechanisms. Front Endocrinol (Lausanne). 2022;13:800995. https://doi.org/10.3389/fendo.2022.800995

35. Atchison EA, Gridley G, Carreon JD, Leitzmann MF, McGlynn KA. Risk of cancer in a large cohort of U.S. veterans with diabetes. Int J Cancer. 2011;128(3):635-643. https://doi.org/10.1002/ijc.25362

36. Jian Gang P, Mo L, Lu Y, Runqi L, Xing Z. Diabetes mellitus and the risk of prostate cancer: an update and cumulative meta-analysis. Endocr Res. 2015;40(1):54-61. https://doi.org/10.3109/07435800.2014.934961

37. Long XJ, Lin S, Sun YN, Zheng ZF. Diabetes mellitus and prostate cancer risk in Asian countries: a meta-analysis. Asian Pac J Cancer Prev. 2012;13(8):4097-4100. https://doi.org/10.7314/apjcp.2012.13.8.4097

38. Rao Kondapally Seshasai S, Kaptoge S, Thompson A, Di Angelantonio E, Gao P, et al. Diabetes mellitus, fasting glucose, and risk of cause-specific death. N Engl J Med. 2011;364(9):829- 841. Erratum in: N Engl J Med. 2011;364(13):1281. https://doi.org/10.1056/NEJMoa1008862

39. Изуткин Д.А. Поведенческие факторы риска и проблема сердечно-сосудистых заболеваний. Медицинский альманах. 2022;(3):21-28

40. Phua ZJ, MacInnis RJ, Jayasekara H. Cigarette smoking and risk of second primary cancer: a systematic review and metaanalysis. Cancer Epidemiol. 2022;78:102160. https://doi.org/10.1016/j.canep.2022.102160

41. Yoo JE, Han K, Shin DW, Kim D, Kim BS, et al. Association Between Changes in Alcohol Consumption and Cancer Risk. JAMA Netw Open. 2022;5(8):e2228544. https://doi.org/10.1001/jamanetworkopen.2022.28544

42. Avraham S, Abu-Sharki S, Shofti R, Haas T, Korin B, et al. Early Cardiac Remodeling Promotes Tumor Growth and Metastasis. Circulation. 2020;142(7):670-683. https://doi.org/10.1161/CIRCULATIONAHA.120.046471

43. Kusiak A, Brady G. Bifurcation of signalling in human innate immune pathways to NF-kB and IRF family activation. Biochem Pharmacol. 2022;205:115246. https://doi.org/10.1016/j.bcp.2022.115246

44. Kusiak A, Brady G. Bifurcation of signalling in human innate immune pathways to NF-kB and IRF family activation. Biochem Pharmacol. 2022;205:115246. https://doi.org/10.1016/j.bcp.2022.115246